Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
G9RRXReE362nxEdE